On Monday, america Patent and Trademark Workplace (USPTO) issued a Discover of Allowance for a key patent utility protecting Anixa Biosciences, Inc.’s ANIX ovarian most cancers vaccine expertise.
The patent consists of broad claims associated to strategies of eliciting an immune response concentrating on the Anti-Mullerian Hormone Receptor, Kind II (AMHR2), a goal for ovarian most cancers prevention and remedy.
Anixa’s ovarian most cancers vaccine is being developed in collaboration with Cleveland Clinic and the Nationwide Most cancers Institute.
The allowed claims embody strategies of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide, particularly the extracellular area of human AMHR2, to elicit an AMHR2-specific immune response.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, commented, “Receiving this Discover of Allowance from the USPTO is a major milestone in our mission to develop a preventative and therapeutic ovarian most cancers vaccine. The allowed claims present broad safety for the assorted elements and supply mechanisms of our vaccine expertise. This strengthens our mental property place and helps the continued development of our program.”
In February, Anixa Biosciences dosed its last affected person within the third cohort of its ongoing Section 1 scientific trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) remedy for recurrent ovarian most cancers.
The examine is being carried out by way of a analysis partnership with Moffitt Most cancers Middle.
The fourth cohort is predicted to start after a 30-day verification that there proceed to be no hostile results skilled by the third cohort.
Worth Motion: ANIX inventory closed at $3.16 on Friday.
Learn Subsequent:
Momentum31.37
Progress–
High quality–
Worth–
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
